Patients, Caregivers and Advocates

SANRECO STUDY

The SANRECO study includes two parts:

  • Part 1, also known as phase 1, was designed to determine the safety and the correct dose/amount of SLN124 (divesiran)
  • Part 2, also known as phase 2, is evaluating how well divesiran works and how often it should be given

The main endpoints of the study are to assess:

  • The reduction of phlebotomy requirements with divesiran treatment
  • The effect of divesiran in reducing PV related symptoms and improving quality of life measures
  • The safety and whether divesiran works in PV patients

The SANRECO phase 2 clinical study is evaluating a potential new treatment, SLN124 (divesiran), for patients with polycythemia vera (PV).

Phase 2 Study

Study Overview
Study Overview
  • Patients will receive either divesiran or placebo by injection (under the skin) every 6 weeks
    • Placebo-controlled Period – 36 weeks (approximately 9 months): Patients will get divesiran or placebo by random assignment. Neither patients nor their doctor will know which one they receive
    • Extension Period: Patients will either continue or switch to divesiran
    • Open-label Period: All participants receive divesiran
How the Study Medication is Being Evaluated
How the Study Medication is Being Evaluated
  • The main goal is to see if divesiran helps keep red blood cell levels normal without the need for phlebotomies
  • Researchers will also track:
    • Quality of life measurements during the study
    • How much divesiran is in the blood
    • Any side effects
Before Treatment Starts
Visits and Time Commitment
  • The SANRECO phase 2 study will last nearly 4 years
  • Patients will be seen at the study site clinic every 6 weeks to receive treatment, health check and response to treatment – these visits can take up to 4 hours
Safety Monitoring and Care
Safety Monitoring and Care
  • Patients will have regular health check-ups, including lab tests and physical exams
SANRECO
SLN124 Phase 1 Results

Divesiran Phase 1 Results

  • Early results from the completed phase 1 portion of the study show divesiran was well-tolerated with no major safety concerns1
  • Patients needed fewer phlebotomies following infrequent dosing of divesiran, when compared to the 12 months prior to the start of treatment11

1. Kremyanskaya, Marina, et al. Initial results from a phase 1/2 study evaluating divesiran, a novel galnac conjugated siRNA, in patients with polycythemia vera (SANRECO). Blood. 2024;144(suppl 1):656. doi:10.1182/blood-2024-205854